



Acquired factor V inhibitor after antibiotic treatment in a patient with pneumonia: a case report

Masaya Taniwaki¹ · Shinya Katsutani² · Masahiro Yamasaki¹ · Kazuma Kawamoto¹ · Kunihiko Funaishi¹ · Yu Matsumoto¹ · Naoko Matsumoto¹ · Nobuyuki Ohashi^{1,3} · Noboru Hattori⁴

Received: 31 January 2019 / Accepted: 4 February 2019 / Published online: 12 February 2019
© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Dear Editor,

Acquired factor V (FV) inhibitor (aFVI) might be induced by antibiotics and may only improve with antibiotic termination. We should consider this disorder to prevent massive bleeding; prothrombin time (PT) and activated partial thromboplastin time (APTT) should be checked before invasive examinations in antibiotic-receiving patients.

A 78-year-old man with a history of smoking 45 packs/year and chronic obstructive pulmonary disease presented to a clinic with high-grade fever. Serum analysis revealed an inflammatory reaction; cefcapene pivoxil was administered. Two days later, the inflammation worsened, and right pneumonia was suspected on chest radiograph. He presented to our hospital for further treatment.

We changed the antibiotic to garenoxacin; however, he showed limited improvement and was admitted to our hospital. Computed tomography showed consolidation and ground-glass shadows in his right lung and a nodule shadow in his left lung. We administered several antibiotics and antifungal agents, including ceftriaxone, levofloxacin, meropenem, and micafungin. His pneumonia improved with treatment; we planned a transbronchial lung biopsy to investigate the nodule shadow observed in his left lung.

For biopsy preparation, we checked PT and APTT, both of which were increased. Later, decreased FV levels were detected and a mixing test was performed (Fig. 1). He was diagnosed with aFVI after antibiotic treatment. After termination of the antibiotics, PT and APTT improved; biopsy was performed safely.

Neutralizing auto-antibodies cause rare bleeding disorders due to acquired deficiencies in coagulation factors [1]. Acquired factor V inhibitor is a rare disorder. Several causes of FV inhibitor have been reported, such as exposure to bovine thrombin, cancer, autoimmune disorders, human immunodeficiency virus infection, infections, amyloidosis, and antibiotics [2–4]. FV inhibitor can be detected by increased PT and APTT, decreased FV levels, and by performing mixing tests or the Bethesda method [2].

We demonstrated two important clinical observations. First, aFVI might be induced by antibiotic treatment. Two patients have been reported to be diagnosed with aFVI following ciprofloxacin treatment [4]. In the present case, the specific antibiotic agent that induced aFVI was unclear; however, aFVI should be considered while

✉ Masaya Taniwaki
graymzo@yahoo.co.jp

¹ Department of Respiratory Disease, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, 1-9-6 Senda-machi, Naka-ku, Hiroshima 730-8619, Japan

² Department of Hematology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Naka-ku, Hiroshima, Japan

³ Ohashi Clinic, Naka-ku, Hiroshima, Japan

⁴ Department of Molecular and Internal Medicine, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan




Fig. 1 Mixing test results showing the inhibitor pattern but not the deficiency pattern. APTT, activated partial thromboplastin time

administering antibiotic treatment to patients, especially before invasive examinations.

Second, in patients with antibiotic-induced aFVI, PT and APTT might only improve by terminating antibiotic administration. In one patient with antibiotic-induced aFVI, normalization was only observed after antibiotic termination [4]. However, aFVI could be demonstrated even after ciprofloxacin termination in another patient [4]. In the present case, several antibiotics were administered for treating pneumonia; PT and APTT only improved following antibiotic termination. Therefore, antibiotic termination and follow-up of PT and APTT might be efficacious in such patients.

In conclusion, we report a case of aFVI after antibiotic treatment. aFVI might be induced by antibiotic treatment and we should consider this disorder, especially before invasive examinations. Patients with aFVI might only improve after antibiotic termination.

Acknowledgements We would like to thank Editage (www.editage.jp) for English language editing.

Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.

Informed consent Informed consent was obtained from all individual participants included in the study.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

1. Ang AL, Kuperan P, Ng CH, Ng HJ (2009) Acquired factor V inhibitor. A problem-based systematic review. *Thromb Haemost* 101:852–859
2. Kane WH, Davie EW (1988) Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. *Blood* 71:539–555
3. Bayani N, Rugina M, Haddad-Vergnes L, Lelong F (2002) High-titer acquired factor V inhibitor responsive to corticosteroids and cyclophosphamide in a patient with two malignant tumors. *Am J Hematol* 71:33–36
4. Miesbach W, Voigt J, Peetz D, Scharrer I (2003) Massive bleeding symptoms in two patients with factor V inhibitor and antiphospholipid antibodies after treatment with ciprofloxacin. *Med Klin (Munich)* 98: 339–343